Literature DB >> 29787390

Genitourinary Syndrome of Menopause.

Jan L Shifren1.   

Abstract

Genitourinary syndrome of menopause (GSM) describes a collection of exam findings and bothersome symptoms associated with estrogen deficiency involving changes to the labia, introitus, clitoris, vagina, urethra, and bladder. Vulvovaginal atrophy is a component of GSM. GSM is a highly prevalent medical condition with adverse effects on the health and quality of life of midlife women. There are many effective treatment options, including nonhormonal lubricants and moisturizers, physical therapy, low-dose vaginal estrogen therapy, vaginal dehydroepiandrosterone, and oral ospemifene. Despite the availability of safe and effective therapies, GSM often remains unrecognized and untreated.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29787390     DOI: 10.1097/GRF.0000000000000380

Source DB:  PubMed          Journal:  Clin Obstet Gynecol        ISSN: 0009-9201            Impact factor:   2.190


  7 in total

1.  Women harmed by vaginal laser for treatment of GSM-the latest casualties of fear and confusion surrounding hormone therapy.

Authors:  Andrew M Kaunitz; JoAnn V Pinkerton; JoAnn E Manson
Journal:  Menopause       Date:  2019-04       Impact factor: 2.953

2.  Ovariectomized mice and postmenopausal women exhibit analogous loss of genital epithelial integrity.

Authors:  Nirk E Quispe Calla; Rodolfo D Vicetti Miguel; Kristen M Aceves; Huijie Huang; Brooke Howitt; Thomas L Cherpes
Journal:  Tissue Barriers       Date:  2021-01-11

Review 3.  Treatment of genitourinary syndrome of menopause: the potential effects of intravaginal ultralow-concentration oestriol and intravaginal dehydroepiandrosterone on quality of life and sexual function.

Authors:  Valentina Lucia La Rosa; Michał Ciebiera; Li-Te Lin; Shangrong Fan; Salvatore Butticè; Thozhukat Sathyapalan; Robert Jędra; Patricia Lordelo; Alessandro Favilli
Journal:  Prz Menopauzalny       Date:  2019-06-28

Review 4.  Hyaluronic Acid: A Valid Therapeutic Option for Early Management of Genitourinary Syndrome of Menopause in Cancer Survivors?

Authors:  Rossella E Nappi; Silvia Martella; Francesca Albani; Chiara Cassani; Ellis Martini; Fabio Landoni
Journal:  Healthcare (Basel)       Date:  2022-08-13

Review 5.  The Genitourinary Syndrome of Menopause: An Overview of the Recent Data.

Authors:  Kyveli Angelou; Themos Grigoriadis; Michail Diakosavvas; Dimitris Zacharakis; Stavros Athanasiou
Journal:  Cureus       Date:  2020-04-08

Review 6.  Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women.

Authors:  Rossella E Nappi; Ellis Martini; Laura Cucinella; Silvia Martella; Lara Tiranini; Alessandra Inzoli; Emanuela Brambilla; David Bosoni; Chiara Cassani; Barbara Gardella
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-21       Impact factor: 5.555

7.  Clinically Used Hormone Formulations Differentially Impact Memory, Anxiety-Like, and Depressive-Like Behaviors in a Rat Model of Transitional Menopause.

Authors:  Stephanie V Koebele; Ryoko Hiroi; Zachary M T Plumley; Ryan Melikian; Alesia V Prakapenka; Shruti Patel; Catherine Carson; Destiney Kirby; Sarah E Mennenga; Loretta P Mayer; Cheryl A Dyer; Heather A Bimonte-Nelson
Journal:  Front Behav Neurosci       Date:  2021-07-21       Impact factor: 3.558

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.